New Jersey’s Attorney General and Division of Consumer Affairs alerted the public that three synthetic kratom-related compounds became illegal to possess or sell in the state under a temporary federal scheduling order. The release describes a controlled-substance alert, not a privacy enforcement action, and identifies no company, privacy violation, or monetary penalty.
No privacy-related remedy or monetary penalty is described. The alert states that the listed compounds are scheduled as illegal to possess or sell in New Jersey, with potential criminal charges for violations.
This release does not describe a privacy enforcement action, so it does not indicate a need to revise privacy or data-processing clauses. Product, procurement, and legal teams dealing in kratom-related products should review supplier and distribution agreements for representations that products and ingredients comply with applicable controlled-substance laws, ingredient and labeling disclosure obligations, prompt notice of regulatory changes, audit or documentation rights, and rights to suspend sales or terminate if an ingredient becomes restricted. Customer-facing terms may also need review for accurate product descriptions and restrictions on sale or possession.
Entity
Mitragynine pseudoindoxyl, MGM-15, and MGM-16
Industry
OtherOfficial Press Release
https://www.njoag.gov/ag-davenport-division-of-consumer-affairs-issue-public-alert-three-types-of-synthetic-kratom-to-be-listed-as-controlled-dangerous-substances-in-new-jersey/
New Jersey Attorney General Enforcement Page
https://www.njoag.gov/about/divisions-and-offices/division-of-consumer-affairs/
"mitragynine pseudoindoxyl, MGM-15, and MGM-16"
"Under New Jersey law, if the federal government schedules a drug and the Director of the Division of Consumer Affairs does not object–which he did not in this case– that drug automatically becomes scheduled in New Jersey too."
"In August 2026, the U.S. Drug Enforcement Administration (DEA) temporarily classified three synthetic compounds related to synthetic kratom–mitragynine pseudoindoxyl, MGM-15, and MGM-16–as Schedule I drugs."
"Starting Today, Anyone Possessing or Selling These Products Could Face Criminal Charges"
"For Immediate Release: September 25, 2026"
New Jersey joined a coalition of state attorneys general in filing a notice in Character Technologies, Inc.’s bankruptcy proceedings, raising concerns about the company’s safety and privacy practices and the sensitive conversations it holds, including those involving children and mental health. The states seek safeguards for consumers’ personal information in any sale or transfer of the company’s business or assets; the release does not report a fine or final finding of violations.
A multistate coalition co-led by New Jersey won a federal court order rejecting the Trump Administration’s decision not to request funding for the CFPB. The order struck down that decision and directed the Administration to follow the law and fund the agency; no monetary penalty or privacy violation is described.
$2.3M
Laboratory Corporation of America Holdings agreed to pay $2,287,455 to participating states and strengthen its security and vendor-management practices following an investigation into the 2019 breach at its debt-collection vendor, AMCA. The breach potentially exposed information of more than 27.5 million people nationwide, including sensitive information belonging to approximately 10.2 million LabCorp patients.
$694.0M
New Jersey's Attorney General and Division of Consumer Affairs, along with 41 Attorneys General, reached a $694 million settlement with subprime auto lender Credit Acceptance Corporation over allegations it originated unaffordable loans its own systems predicted borrowers could not repay, employed aggressive debt-collection tactics, and failed to prevent deceptive vehicle-service contract and GAP product 'packing' by dealers. The multistate settlement stepped in after the CFPB permanently dropped its 2023 enforcement action against CAC in 2025. CAC will provide $60 million in cash restitution, $634 million in debt relief, an additional $15 million to the states, and implement injunctive lending reforms including loan off ramps, pre-loan disclosures, add-on packing safeguards, and a seven-year vehicle price cap. Note: this is a consumer-protection lending enforcement action, not a privacy matter; violation categories are best-fit mappings from the available taxonomy.
$650K
The New Jersey Attorney General and Division of Consumer Affairs announced that Match Group, Inc. will pay $650,000 and change its business practices to settle allegations that it misrepresented or failed to disclose its criminal background screening policies and practices to New Jersey users, violating the New Jersey Consumer Fraud Act and the Internet Dating Safety Act. Under a Consent Order, Match must accurately represent its screening policies, notify existing New Jersey members of updated disclosures within 150 days, and post clear and conspicuous disclosures and safety notifications about the limitations of criminal background screenings.
$96.5M
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.